ONC Stock Analysis: Buy, Sell, or Hold?
ONC - BeOne Medicines Ltd. American Depositary Shares
$284.95
1.92 (0.68%)
▲
5d:
+3.72%
30d:
-10.11%
90d:
-8.78%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 06, 2026
Get Alerted When ONC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ONC trading at deep discount. Market pricing in -13.4% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: ONC trading at deep discount. Market pricing in -13.4% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$451.14
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$280.13
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ONC is currently trading at $284.95, which is considered slightly low relative to its 30-day fair value range of $274.95 to $333.94. From a valuation perspective, the stock is trading at a discount (Forward PE: 30.5) compared to its historical average (46.9). Remarkably, the market is currently pricing in an annual earnings decline of 13.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ONC is in a downtrend. The price is approaching resistance at $292.94. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $408.32 (+44.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ONC is in a downtrend. The price is approaching resistance at $292.94. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $408.32 (+44.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$274.95 -
$333.94
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 44.3% below Wall St target ($408.32)
Fair Price Analysis
30-Day Fair Range
$274.95 -
$333.94
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$18.25
(6.4%)
Support & Resistance Levels
Support Level
$271.47
Resistance Level
$292.94
Current Trend
Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
30.54
Wall Street Target
$408.32
(+44.3%)
Revenue Growth (YoY)
32.8%
Profit Margin
5.4%
Valuation Discount vs History
-13.4% cheaper
PE vs Historical
30.5 vs 46.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-13.4%
(market-implied from PE analysis)
1-Year Target
$254.73
(-10%)
2-Year Target
$229.25
(-19%)
3-Year Target
$206.33
(-27%)
3-Yr Target (if PE normalizes)
(PE: 31→47)
$316.83
(+12%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 30.5, Growth: 68.5%)
$955.23
(+238%)
Base:
(SPY PE: 22.4, Growth: 68.5%)
$700.57
(+148%)
Bear:
(PE: 19.0, Growth: 68.5%)
$595.48
(+110%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (48x PE), but valuation improves significantly next year (31x PE) as earnings recover.
Forward PE: 47.62 | Forward EPS (Implied): $5.77
Bull Case
$331.74
(+21%)
Analyst growth 15.0%, PE expands to 50.0
Base Case
$274.73
(0%)
Market implied 0.0%, PE stable at 47.6
Bear Case
$210.17
(-24%)
Severe decline -15.0%, PE contracts to 42.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 30.5 to 46.9
Stabilization Target:
$434.61
(+53.6%)
PE Expansion Potential:
+53.6%
Share & Embed Analysis
Last updated: March 30, 2026 12:12 PM ET
Data refreshes hourly during market hours. Next update: 1:12 PM
Data refreshes hourly during market hours. Next update: 1:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ONC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
13
Sells
Net
INSIDERS SELLING
Recent Transactions
Chan Henry Lee
SELL
341 shares
2026-03-11
Chan Henry Lee
SELL
1660 shares
2026-02-04
Chan Henry Lee
SELL
664 shares
2026-01-07
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 49 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 53 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 58 HOLD |